# Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

> **NCT06446388** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** QLS31905
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** QL1706
- **DRUG:** Chemotherapy drug

## Key facts

- **NCT ID:** NCT06446388
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-01
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446388, "Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06446388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*